LEMTRADA
Drug
GENZYME CORPORATION
Total Payments
$37.6M
Transactions
46,375
Doctors
4,095
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $108,874 | 84 | 22 |
| 2023 | $313,788 | 225 | 96 |
| 2022 | $354,232 | 224 | 32 |
| 2021 | $1.7M | 505 | 193 |
| 2020 | $1.4M | 1,731 | 579 |
| 2019 | $7.2M | 10,342 | 2,047 |
| 2018 | $11.8M | 15,227 | 2,486 |
| 2017 | $14.6M | 18,037 | 2,612 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.0M | 4,284 | 45.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14.3M | 4,555 | 38.1% |
| Consulting Fee | $3.1M | 456 | 8.2% |
| Travel and Lodging | $2.2M | 7,076 | 6.0% |
| Food and Beverage | $899,204 | 29,874 | 2.4% |
| Gift | $19,683 | 1 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $16,750 | 9 | 0.0% |
| Education | $7,530 | 120 | 0.0% |
Payments by Type
General
$20.6M
42,091 transactions
Research
$17.0M
4,284 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Lemtrada TOPAZ - Global AED | GENZYME CORPORATION | $4.2M | 2 |
| A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | GENZYME CORPORATION | $3.3M | 23 |
| A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | SANOFI US SERVICES INC. | $2.0M | 0 |
| A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) | GENZYME CORPORATION | $1.2M | 2 |
| Sequential natalizumab ? alemtuzumab therapy in patients with relapsing forms of multiple sclerosis | GENZYME CORPORATION | $680,123 | 0 |
| Phase I Trial Monitoring Efficacy and Safety in Treatment of Alemtuzumab Naive Subjects and Data Collecting and Monitoring of Alemtuzumab Experienced Subjects with Refractory Multiple Sclerosis | GENZYME CORPORATION | $612,315 | 0 |
| Prospective Cross Sectional Study To Assess The Clinical Utility Of Optical Coherence Tomography (OCT) To Measure Axonal Degeneration Of The Optic Nerve Using Retinal Nerve Fiber Layer (RNFL) And Ganglion Cell Layer (GCL) Analysis In A Cohort Of 150-200 Subjects Meeting The Diagnostic Criteria Of Multiple Sclerosis (MS) | GENZYME CORPORATION | $532,413 | 0 |
| Lemtrada PRO-ACT study | GENZYME CORPORATION | $439,414 | 1 |
| Measuring active microglia in progressive multiple sclerosis | GENZYME CORPORATION | $435,042 | 0 |
| A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multi | GENZYME CORPORATION | $394,606 | 2 |
| LEMTRADA LEMCOG study US | GENZYME CORPORATION | $322,801 | 0 |
| Assessing the induction of long-term immune regulation following treatment with Lemtrada (Alemtuzumab). | GENZYME CORPORATION | $260,313 | 0 |
| EXTERNAL COLLABORATION - In Vivo Perturb-Seq: Single Cell Analysis of Immune Function with Alemtuzumab Treatment in Multiple Sclerosis | GENZYME CORPORATION | $232,568 | 0 |
| Mechanisms of action of mu aCD52 mAb: the role of T-regulatory cells in the immunological reconstitution and long-lasting disease activity suppression in experimental autoimmune encephalomyelitis (EAE) | GENZYME CORPORATION | $225,750 | 0 |
| Assessing the induction of long-term immune regulation following treatment with Lemtrada? (Alemtuzumab). | GENZYME CORPORATION | $195,138 | 0 |
| Biomarkers of Disease Heterogeneity in Multiple Sclerosis: Phase II | GENZYME CORPORATION | $178,970 | 0 |
| Prospective Cross Sectional Study To Assess The Clinical Utility Of Optical Coherence Tomography (OCT) To Measure Axonal Degeneration Of The Optic Nerve Using Retinal Nerve Fiber Layer (RNFL) And Gang | GENZYME CORPORATION | $173,850 | 0 |
| A Prospective 24-Month Observational Study of Neurocognitive Function and Safety in Patients with Relapsing Multiple Sclerosis Who Are Initiating LEMTRADA Treatment | GENZYME CORPORATION | $163,166 | 0 |
| In Vivo Perturb-Seq: Single Cell Analysis of Immune Function with Alemtuzumab Treatment in Multiple Sclerosis | SANOFI US SERVICES INC. | $159,892 | 0 |
| A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA Treatment In patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modif | GENZYME CORPORATION | $148,015 | 4 |
Top Doctors Receiving Payments for LEMTRADA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Neurology | Natrona Heights, PA | $117,938 | 157 |
| , M.D | Neurology | Norwood, MA | $117,417 | 111 |
| , MD | Neurology | Naperville, IL | $113,971 | 110 |
| , MD | Neurology | Sarasota, FL | $113,005 | 154 |
| , D.O | Neurology | Phoenix, AZ | $111,845 | 186 |
| , MD | Neurology | Audubon, NJ | $111,607 | 133 |
| , M.D | Hematology | Tampa, FL | $109,002 | 1 |
| , MD | Neurology | Rye Brook, NY | $106,899 | 99 |
| , MD | Pediatric Hematology-Oncology | Augusta, GA | $106,728 | 87 |
| , M.D | Neurology | Philadelphia, PA | $106,393 | 101 |
| , MD | Neuromuscular Medicine | Stanford, CA | $101,601 | 101 |
| , M.D | Neurology | Plainview, NY | $100,061 | 75 |
| , MD | Neurology | Brighton, MA | $99,427 | 134 |
| , M.D | Neurology | Houston, TX | $98,622 | 29 |
| Douglas Lewis | — | Amarillo, TX | $97,447 | 119 |
| , MD | Neurology | Providence, RI | $97,248 | 60 |
| , MD | Neurology | Fullerton, CA | $95,690 | 169 |
| , M.D | Neurology | Oldsmar, FL | $91,254 | 175 |
| , D.O | Neurology | Milwaukee, WI | $90,887 | 101 |
| , MD, PHD | Neurology | Seattle, WA | $90,233 | 120 |
| , D.O | Neurology | Farmington Hills, MI | $87,576 | 79 |
| , M.D | Neurology | Oklahoma City, OK | $82,162 | 83 |
| , MD | Neurology | New Orleans, LA | $80,738 | 108 |
| , MD | Neurology | Spokane, WA | $80,599 | 91 |
| , DO | Neurology | Wesley Chapel, FL | $78,695 | 107 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $33.5M
- SANOFI US SERVICES INC. $2.6M
- SANOFI-AVENTIS U.S. LLC $1.4M
Product Information
- Type Drug
- Total Payments $37.6M
- Total Doctors 4,095
- Transactions 46,375
About LEMTRADA
LEMTRADA is a drug associated with $37.6M in payments to 4,095 healthcare providers, recorded across 46,375 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2024. In 2024, $108,874 was paid across 84 transactions to 22 doctors.
The most common payment nature for LEMTRADA is "Unspecified" ($17.0M, 45.2% of total).
LEMTRADA is associated with 20 research studies, including "Lemtrada TOPAZ - Global AED" ($4.2M).